Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications

被引：38
作者：
Bjerre, Mette [1 ]
机构：
[1] Aarhus Univ, Fac Hlth, Dept Clin Med, Med Res Lab, Norrebrogade 44,Bldg 3b, DK-8000 Aarhus C, Denmark
来源：
SPRINGERPLUS | 2013年 / 2卷
关键词：
Osteoprotegerin; OPG; Diabetes; Cardiovascular disease; Biomarker; KAPPA-B LIGAND; PLASMA OSTEOPROTEGERIN; RECEPTOR ACTIVATOR; MYOCARDIAL-INFARCTION; SERUM OSTEOPROTEGERIN; GENE POLYMORPHISMS; KIDNEY-FUNCTION; RISK-FACTORS; BONE; MORTALITY;
D O I：
10.1186/2193-1801-2-658
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Osteoprotegerin (OPG) is a glycoprotein involved in bone metabolisms and with a regulatory role in immune, skeletal and vascular systems. Recently, circulating OPG levels have emerged as independent biomarkers of cardiovascular disease (CVD) in patients with acute or chronic heart disease, as well as in the healthy population. Furthermore, OPG has been implicated in various inflammations and linked to diabetes and poor glycaemic control. This review focuses on the relations between circulating OPG levels and cardiovascular complications, with special emphasis on diabetic patients. OPG levels were observed to increase concurrently with the severity of diabetic complications, that is, with the highest circulating OPG levels observed in diabetic patients dying from CVD. Although the clinical prognostic use of OPG may seem far away, OPG does look promising as a biomarker in order to help the cardiologist to a better risk-stratification of the patients.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 60 条
[1]   Relation of osteoprotegerin to coronary calcium and aortic plaque (from The Dallas Heart Study) [J].
Abedin, Moeen ;
Omland, Torbjorn ;
Ueland, Thor ;
Khera, Amit ;
Aukrust, Pal ;
Murphy, Sabina A. ;
Jain, Tulika ;
Gruntmanis, Ugis ;
McGuire, Darren K. ;
de Lemos, James A. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (04) :513-518
[2]   The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects [J].
Anand, DV ;
Lahiri, A ;
Lim, E ;
Hopkins, D ;
Corder, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (09) :1850-1857
[3]   Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size [J].
Andersen, Geir Oystein ;
Knudsen, Eva Cecilie ;
Aukrust, Pal ;
Yndestad, Arne ;
Oie, Erik ;
Muller, Carl ;
Seljeflot, Ingebjorg ;
Ueland, Thor .
HEART, 2011, 97 (06) :460-465
[4]   Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice [J].
Bennett, Brian J. ;
Scatena, Marta ;
Kirk, Elizabeth A. ;
Rattazzi, Marcello ;
Varon, Rebecca M. ;
Averill, Michelle ;
Schwartz, Stephen M. ;
Giachelli, Cecilia M. ;
Rosenfeld, Michael E. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2117-2124
[5]   Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients [J].
Biscetti, Federico ;
Straface, Giuseppe ;
Giovannini, Silvia ;
Santoliquido, Angelo ;
Angelini, Flavia ;
Santoro, Luca ;
Porreca, Carlo Filippo ;
Pecorini, Giovanni ;
Ghirlanda, Giovanni ;
Flex, Andrea .
HUMAN GENETICS, 2013, 132 (01) :49-55
[6]   A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function [J].
Brändström, H ;
Stiger, F ;
Lind, L ;
Kahan, T ;
Melhus, H ;
Kindmark, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (01) :13-17
[7]   Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].
Browner, WS ;
Lui, LY ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637
[8]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[9]   Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum [J].
Chan, BYY ;
Buckley, KA ;
Durham, BH ;
Gallagher, JA ;
Fraser, WD .
CLINICAL CHEMISTRY, 2003, 49 (12) :2083-2085
[10]   Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men [J].
Chen, Weena J. Y. ;
Rijzewijk, Luuk J. ;
van der Meer, Rutger W. ;
Heymans, Martijn W. ;
van Duinkerken, Eelco ;
Lubberink, Mark ;
Lammertsma, Adriaan A. ;
Lamb, Hildo J. ;
de Roos, Albert ;
Romijn, Johannes A. ;
Smit, Jan W. A. ;
Bax, Jeroen J. ;
Bjerre, Mette ;
Frystyk, Jan ;
Flyvbjerg, Allan ;
Diamant, Michaela .
CARDIOVASCULAR DIABETOLOGY, 2011, 10
123456